Authors’ response to letter on “levetiracetam in toxic seizures”

Ted LeeUniversity of New Mexico, Emergency Medicine, Albuquerque, NM, USA;

Brandon J. WarrickNew Mexico Poison and Drug Information Center, University of New Mexico, Emergency Medicine, Albuquerque, NM, USA;

Preeyaporn SarangarmUniversity of New Mexico Hospital, Department of Pharmacy, Albuquerque, NM, USA;

Robert L. AlundayUniversity of New Mexico, Department of Neurosurgery, Albuquerque, NM, USA;

Silas BussmannUniversity of New Mexico, Emergency Medicine, Albuquerque, NM, USA;

Susan C. SmolinskeNew Mexico Poison and Drug Information Center, University of New Mexico, Pharmacy Practice and Administration, Albuquerque, NM, USA;

Steven A. SeifertDepartment of Emergency Medicine, University of New Mexico School of Medicine, New Mexico Poison and Drug Information Center, Albuquerque, NM, USA

show all

References

Lyseng-Williamson KA. Spotlight on levetiracetam in epilepsy. CNS Drugs. 2011;25:901–905.
PubMed Web of Science ®Google Scholar
Beran RG, Berkovic SF, Black AB, et al. Efficacy and safety of levetiracetam 1000–3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study. Epilepsy Res. 2005;63:1–9.
PubMed Web of Science ®Google Scholar
Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia. 2001;42 Suppl 4:31–35.
PubMed Web of Science ®Google Scholar
Mundlamuri RC, Sinha S, Subbakrishna DK, et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam-pilot study. Epilepsy Res. 2015;114:52–58.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Authors’ response to letter on “levetiracetam in toxic seizures”

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Authors’ response to letter on “levetiracetam in toxic seizures”

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date